Chairman of the Board
Chaim Hurvitz joined Galmed’s Board in 2011.
Mr. Hurvitz currently serves as the CEO of CH Health, a private venture capital firm; a position he has held since 2011. Previously, he was a member of Teva’s senior management team, serving as the President of Teva International Group from 2002 until 2010, as President and CEO of Teva Pharmaceuticals Europe from 1992 to 1999 and as Vice President, Israeli Pharmaceutical Sales from 1999 until 2002.
Additionally, from 2010 until 2014, Mr. Hurvitz served as a member of the Board of Directors of Teva Pharmaceuticals Industries Ltd.
Mr. Hurvitz presently serves as the chairman of Polypid, Aerodentis and the Jaffa Institute, and is a board member of Urogen and Cellixir. He is also a board member of the Manufacturers Association of Israel, and chairs its pharmaceutical branch.
He holds a Bachelor of Arts degree in political science and economics from Tel Aviv University, which awarded in 1985.
Mr. Baharaff is the co‐founder of Galmed, and has served as CEO since 2012, and President as of 2015. Previously, he held a number of senior executive positions, including SVP at Isramex Projects Ltd., and Managing Director of T+M Trusteeship & Management. He also serves as a Director of the Tel‐Aviv Museum of Arts and Executive Director at The Rubin Museum.
Mr. Baharaff holds a Bachelor of Science degree from the University of London (LSE) and LLB and MA degrees from Cambridge University. Since 1993, Mr. Baharaff has been a member of the Israel Bar Association.
Carol L. Brosgart, M.D.
Dr. Brosgart has served as a member of Galmed’s board of directors since 2017. Dr. Brosgart served as a member of Tobira Therapeutics’s Board of Directors from 2009 until it was acquired by Allergan in 2016. She is now a consultant to Allergan and a number of biotechnology companies in the areas of liver disease and infectious disease. Dr. Brosgart currently serves on the Steering Committee of the National Viral Hepatitis Roundtable, the Executive Committee of the Forum for Collaborative Research, and the Steering Committee of the HBV Cure Group at the Forum. She is active in the public policy arena for AASLD and IDSA/HIVMA.
Dr. Brosgart served as Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and to the Viral Hepatitis Action Coalition at the CDC Foundation from 2011 to 2013. Dr. Brosgart has also served as a member on the faculty of the School of Medicine at the University of California, San Francisco for the past three decades, where she is a Clinical Professor of Medicine, Biostatistics and Epidemiology in the Division of Global Health and Infectious Diseases. From 2011 until 2011, Dr. Brosgart served as Chief Medical Officer at biotechnology company Alios BioPharma, Inc. Prior to Alios, Dr. Brosgart served as Senior Vice President and Chief Medical Officer of Children’s Hospital & Research Center in Oakland, California, from 2009 until February 2011.
Previously, she served for eleven years, from 1998 until 2009, at the biopharmaceutical company Gilead Sciences, Inc., where she held a number of senior management roles, most recently as Vice President, Public Health and Policy and earlier as Vice President, Clinical Research and Vice President, Medical Affairs and Global Medical Director, Hepatitis. She led the clinical development of a number of agents at Gilead, including Viread and Hepsera. Prior to Gilead, Dr. Brosgart worked for more than 20 years in clinical care, research and teaching at several Bay Area medical centers. She was the founder and Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California, from 1987 until 1998 and served as the Medical Director of Central Health Center, Oakland, California, of the Alameda County Health Care Services Agency.
Dr. Brosgart has also served on the boards of privately held companies and public, not‐for‐profit domestic and global health organizations. Dr. Brosgart received a B.S. in Community Medicine from the University of California, Berkeley and received an M.D. from the University of California, San Francisco. Her residency training was in pediatrics, public health and preventive medicine at UCSF and UC Berkeley School of Public Health. She has published extensively in the areas of HIV, HBV, CMV, and liver disease.
William S. Marth
Mr. Marth has served as a member of Galmed’s board of directors since 2014. Mr. Marth currently serves as President and Chief Executive Officer of Albany Molecular Research Inc. (AMRI) a position he has held since 2014. Mr. Marth is also former Director and Chairman of the Board of AMRI. From 2010 to 2012, Mr. Marth served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., in the Americas. From 2008 to 2010, he served as Chief Executive Officer of Teva North America. From 2005 to 2008, Mr. Marth served as CEO of Teva USA.
In addition, Mr. Marth worked with several large equity firms providing guidance on their healthcare investments. He was a member of Teva’s global executive management team from 2007 to 2012. From 1999 to 2002, he was the Executive Vice President and Vice President of Sales and Marketing for Teva USA. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol‐Myers Squibb Co. Mr. Marth is a pharmacist and is currently the Chairman of the Board of Directors of Sorrento Therapeutics, and a director at the University of Illinois at Chicago College of Pharmacy (UIC).
Previously, Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health‐System Pharmacists (ASHP) in 2010, and various boards and committees, including the University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins’ Project Project RESTORE. Mr. Marth earned his B.Sc. in Pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University.
David Sidransky, M.D.
Dr. David Sidransky, has served as a member of Galmed’s board of directors since 2014. Dr. Sidransky is a renowned oncologist and research scientist who was profiled by TIME magazine in 2001 as one of the top physicians and scientists in America. He is widely recognized for his work with early detection of cancer. Dr. Sidransky serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital.
He has authored more than 500 peer‐reviewed publications, and has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the American Association of Cancer Research. Dr. Sidransky previously served as Vice Chairman of the Board of Directors of ImClone.
He is Chairman of the Board of Advaxis Inc, Champions Oncology, and Tamir Biotechnology, and is on the Board of Directors of Rosetta Genomics Ltd and Orgenesis. He is a current and previous member of scientific advisory boards of corporations and institutions, including Amgen, MedImmune, Roche and Veridex, LLC (a Johnson & Johnson diagnostic company). In addition, Dr. Sidransky served as Director of The American Association for Cancer Research from 2005 to 2008. He received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.
Ran Oren, M.D.
Prof. Ran Oren, M.D. joined Galmed’s board of directors in, 2017 and serves as a member of our scientific advisory board since 2014. He has also served as the Company’s Chief Medical Officer from August 2016 to March 2017. Prof. Oren is a Professor of Gastroenterology & Hepatology at the Faculty of Medicine, Hebrew University of Jerusalem, Israel, and he is currently the Head of the Institute of Gastroenterology and Liver Disease at Hadassah Ein Kerem Hopital, Jerusalem, Israel. In 2000, Prof. Oren established the Liver Unit at the Tel Aviv Sourasky Medical Center, where he also served as Chief of Medicine from 2008 to 2010. Prof. Oren concurrently served as the President of the Israeli Association for the Study of the Liver between 2007 and 2010.
Prof. Oren has published over the years in the fields of liver fibrosis, thyroid hormone effect on liver diseases and hepatocyte transplantation. In recent years his main research interests are in the field of non‐alcoholic fatty liver disease (NAFLD) –epidemiology, risk factors, diagnosis and treatment. Prof. Oren currently serves on the editorial board of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD), and recently was the author of The Liver and Pregnancy chapter in the Zakim & Boyer textbook of Hepatology. He received his M.D. from the Hebrew University of Jerusalem, Israel.
Tali Yaron‐Eldar, an Israeli attorney specializing in taxation, has served as a member of Galmed’s board of directors since 2014. Ms. Yaron‐Eldar co‐founded Yaron‐Eldar, Paller, Schwartz & Co. Law Offices in 2013. She was a partner at the law firm of Tadmor & Co. from 2007 through 2012, and a partner at the law firm of Cohen, Yaron‐Eldar & Co. between 2004 and 2007. From 2004 until 2008, Ms. Yaron‐Eldar served as the Chief Executive Officer of Arazim Investment Company. She has served in a variety of public positions, including as Chief Legal Advisor to the Customs and V.A.T Department of the Finance Ministry of the State of Israel from 1998 to 2001, and to the Commissioner of Income Tax and Real Property Tax Authority of the State of Israel from 2002 to 2004.
Ms. Yaron‐Eldar also serves as a Director for a number of public companies, including Rossetta Genomics Ltd., Medtechnica Ltd., Magicjack Vocaltec Ltd., Lodgia Rotex Investments Ltd., Arko Holdings Ltd., Greenergy Renewable Energy Ltd., GO.D.M Investments Ltd. and Tadea Technological Development and Automation Ltd. She earned her M.B.A. specializing in finance in 1995, and her LL.B. in 1987, both from Tel Aviv University. Ms. Yaron‐Eldar is a member of the Israeli Bar Association.
Shmuel Nir, has served as a member of Galmed’s board of directors since 2007. Mr. Nir serves as President and Chief Executive Officer of Tushia Consulting Engineers Ltd., and as Chairman of the Board of Directors of Matan Digital Printers Ltd. From 1998 to 2008, he served as President and Chief Executive Officer of Macpell Industries Ltd.
Between 1991 and 1998, Mr. Nir was Executive Vice President of Operations at Macpell Industries Ltd. and President and Chief Executive Officer of two of its subsidiaries: New Net Industries Ltd., and New Net Assets Ltd. Prior to 1991, Mr. Nir held management positions with Intel Corporation in Jerusalem, Israel and Tefen Management Consulting. Between 1999 and 2006, Mr. Nir served as Managing Partner at Spring Venture Capital Fund. He earned a B.Sc. in Industrial Engineering and Management from the Technion — Israel Institute of Technology in Haifa in 1989.
Mr. Heinberg has extensive experience relevant to the Company and insight into the global capital markets, and has worked with several life science and technology companies. Mr. Heinberg serves as a Senior Advisor to Burford Capital and is the founder and Managing Director of MAH Associates, LLC, which provides strategic advisory and consulting services to various companies, including the Company since 2013. Since April 2017, Mr. Heinberg has served on the board of directors of Ecology and Environment (NasdaqGM: EEI) and is currently Executive Chairman of the Board of Directors. Since January 2010, Mr. Heinberg has served on the board of directors of Universal Biosensors (UBI.AX). Mr. Heinberg began his investment banking career in 1987 in the Corporate Finance Division of Oppenheimer & Co, Inc., which was acquired by Canadian Imperial Bank of Commerce (CIBC) in 1997. Mr. Heinberg served as Head of the Investment Banking Department and as a Senior Managing Director of Oppenheimer & Co. Inc. from 2008 until 2012, and as the U.S. Head of Investment Banking at CIBC World Markets from 2001 until 2008. Mr. Heinberg has also served as a director of National Financial Partners Corp., a business that provided advisory and brokerage services to corporate and high net worth individual clients in the United States and Canada until the company was acquired by Madison Dearborn in July 2013. Mr. Heinberg was also a non‐executive director of Image Entertainment, Inc., a leading independent licensee and distributor of entertainment programming in North America, until the Company was acquired in October 2012. Prior to joining Oppenheimer, Mr. Heinberg practiced corporate law for approximately four years. Mr. Heinberg has a B.S. in economics from the Wharton School at the University of Pennsylvania and a J.D. from Fordham Law School.